ResMed Inc. vs Wix.Com Ltd — how do they compare? ResMed Inc. trades at $230.96 (market cap $31.89B), while Wix.Com Ltd trades at $74.92 (market cap $3.11B). The key difference: ResMed Inc. is far larger — about 10.3× Wix.Com Ltd's market cap, and ResMed Inc. pays a 1.16% dividend while Wix.Com Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Wix.Com Ltd for 62 Days on average.
| RMD | WIX | |
|---|---|---|
Market Cap | $31.89B | $3.11B |
Volume | 618,314 | 809,286 |
Sector | Health | Technology |
52-Week High | $277.88 | $145.54 |
52-Week Low | $182.82 | $40.43 |
Typical Hold Time | 51 Days | 62 Days |
Enterprise Value | $31.24B | $4.19B |
Dividend Yield | 1.16% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
WIX trades at $75.06, up 2.86% today, near the consensus price target of $77.00. The stock shows mixed technical signals with a neutral overall rating but bullish moving averages. Revenue growth is strong, reaching $1.99 billion in 2025, though net income turned positive only recently. However, negative shareholder equity and a class action lawsuit filed in September 2026 present significant headwinds. Analyst sentiment remains largely positive with 63% buy ratings, but recent earnings misses add caution.
The outlook is cautiously optimistic given solid revenue expansion and analyst support, but high valuation multiples, litigation overhang, and inconsistent profitability pose risks. Investors should weigh growth potential against financial stability concerns and legal uncertainties before committing capital.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →